<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985021</url>
  </required_header>
  <id_info>
    <org_study_id>PugetSoundVA</org_study_id>
    <nct_id>NCT02985021</nct_id>
  </id_info>
  <brief_title>Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies</brief_title>
  <official_title>A Phase 2 Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer and Germline or Somatic DNA Repair Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Institute for Biomedical and Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prostate Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Institute for Biomedical and Clinical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients who have metastatic prostate cancer that does not respond to hormone&#xD;
      treatment and who have mutations in certain cancer-related genes will be treated with&#xD;
      docetaxel and carboplatin chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2 study of the combination of docetaxel and carboplatin in patients with&#xD;
      germline inactivation of genes in the homologous recombination pathway, including BRCA1,&#xD;
      BRCA2, and Ataxia Telangiectasia Mutated (ATM).&#xD;
&#xD;
      PRIMARY OBJECTIVE To assess rate of 50% Prostate Specific Androgen (PSA) decline to docetaxel&#xD;
      and carboplatin&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Competing studies&#xD;
  </why_stopped>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">April 2021</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Achieving &gt;= 50% Reduction in PSA According to Prostate Cancer Working Group 3 (PCWG3) Criteria</measure>
    <time_frame>From Day 1 of treatment and up to 30 days after completion of treatment (typically up to 10 cycles of chemotherapy)</time_frame>
    <description>Achievement of a PSA50 decline is whether the treatment results in a 50% or greater decline in PSA from baseline PSA prior to therapy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Hormone-Resistant Prostate Cancer</condition>
  <condition>Metastatic Prostate Carcinoma</condition>
  <condition>Recurrent Prostate Carcinoma</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (docetaxel, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 60 mg/m2 will be administered on Day 1 of each 21-day cycle. Carboplatin Area Under the Curve (AUC) 5 will be administered on Day 1 of each 21-day cycle.&#xD;
Docetaxel and carboplatin should be administered per institutional guidelines. Treatment will be repeated until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Treatment (docetaxel, carboplatin)</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Treatment (docetaxel, carboplatin)</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients meeting the following inclusion criteria will be eligible to participate in this&#xD;
        study:&#xD;
&#xD;
          1. Signed informed consent form (ICF) providing agreement to adhere to the dosing&#xD;
             schedule, report for all trial visits and authorization, use and release of health and&#xD;
             research trial information.&#xD;
&#xD;
          2. Age &gt; 18 years&#xD;
&#xD;
          3. Known prostate cancer&#xD;
&#xD;
          4. Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone&#xD;
             (GnRH) analogues, antagonists or orchiectomy. Patients who have not had an orchiectomy&#xD;
             must be maintained on effective GnRH analogue/antagonist therapy.&#xD;
&#xD;
          5. Castration resistant prostate cancer as defined by serum testosterone &lt; 50ng/ml and&#xD;
             one of the following:&#xD;
&#xD;
               -  PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions&#xD;
                  at least 1 week apart.&#xD;
&#xD;
               -  Evaluable disease progression by modified RECIST (Response Evaluation Criteria in&#xD;
                  Solid Tumors).&#xD;
&#xD;
               -  Progression of metastatic bone disease on bone scan with &gt; 2 new lesions.&#xD;
&#xD;
          6. Prior therapy with abiraterone acetate, enzalutamide, or docetaxel. There is no limit&#xD;
             to the number of prior treatment regimens.&#xD;
&#xD;
          7. Presence of metastatic disease on scans.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) Performance Status of â‰¤ 2.&#xD;
&#xD;
          9. Life expectancy &gt;12 weeks.&#xD;
&#xD;
         10. No prior malignancy is allowed except:&#xD;
&#xD;
               -  Adequately treated basal cell or squamous cell skin cancer or&#xD;
&#xD;
               -  In situ carcinoma of any site or&#xD;
&#xD;
               -  Other adequately treated malignancy for which the patient has been disease-free&#xD;
                  for at least one year (any prior chemotherapy is allowed).&#xD;
&#xD;
         11. Patients must have adequate organ and marrow function as defined below obtained within&#xD;
             14 days prior to start of therapy:&#xD;
&#xD;
               1. Absolute neutrophil count &gt;1.5 x 109 cells/L&#xD;
&#xD;
               2. Hgb &gt; 9.0 g/dL&#xD;
&#xD;
               3. Platelets &gt;100,000 x 109/L&#xD;
&#xD;
               4. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total&#xD;
                  bilirubin levels &lt; 1.5 x Upper Limit of Normal (ULN)&#xD;
&#xD;
         12. Presence of germline inactivation of BRCA1, BRCA2, ATM OR one of the following:&#xD;
&#xD;
               -  Patients with clearly deleterious germline mutations of other genes involved in&#xD;
                  homologous DNA repair may be included at the investigator's discretion.&#xD;
&#xD;
               -  Patients with homozygous inactivation of genes involved in homologous&#xD;
                  recombination from primary or metastatic tumor as assessed by a Clinical&#xD;
                  Laboratory Improvement Amendments (CLIA) level assay for DNA sequencing may be&#xD;
                  included.&#xD;
&#xD;
               -  Patients with a signature of homologous recombination deficiency in primary or&#xD;
                  metastatic tissue may be included (VA Puget Sound only).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patients who meet any of the following criteria will be excluded from the study:&#xD;
&#xD;
          1. Currently receiving active therapy for other neoplastic disorders.&#xD;
&#xD;
          2. Histologic evidence of small cell carcinoma (morphology alone - immunohistochemical&#xD;
             evidence of neuroendocrine differentiation without morphologic evidence is not&#xD;
             exclusionary).&#xD;
&#xD;
          3. Prior treatment with platinum-based chemotherapy for prostate cancer.&#xD;
&#xD;
          4. Known parenchymal brain metastasis.&#xD;
&#xD;
          5. Active or symptomatic viral hepatitis or chronic liver disease.&#xD;
&#xD;
          6. Clinically significant heart disease as evidenced by myocardial infarction, or&#xD;
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New&#xD;
             York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction&#xD;
             measurement of &lt; 35 % at baseline, if done.&#xD;
&#xD;
          7. Treatment with an investigational therapeutic within 30 days of Cycle 1.&#xD;
&#xD;
          8. Patients with dementia/psychiatric illness/social situations limiting compliance with&#xD;
             study requirements or understanding and/or giving of informed consent are not eligible&#xD;
&#xD;
          9. Any medical conditions, which, in the opinion of the investigators, would jeopardize&#xD;
             either the patient or the integrity of the data obtained are not eligible.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert B Montgomery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound HCS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Rettig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Greater Los Angeles HCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Greater Los Angeles - West LA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Ann Arbor Health Care System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <results_first_submitted>April 19, 2021</results_first_submitted>
  <results_first_submitted_qc>August 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2021</results_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>DNA Repair-Deficiency Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02985021/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02985021/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Docetaxel, Carboplatin)</title>
          <description>Docetaxel 60 mg/m2 will be administered on Day 1 of each 21-day cycle. Carboplatin Area Under the Curve (AUC) 5 will be administered on Day 1 of each 21-day cycle.&#xD;
Docetaxel and carboplatin should be administered per institutional guidelines. Treatment will be repeated until disease progression or unacceptable toxicity.&#xD;
Carboplatin: Chemotherapy&#xD;
Docetaxel: Chemotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inability to comply with study procedures</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with metastatic, resistant prostate cancer</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Docetaxel, Carboplatin)</title>
          <description>Docetaxel 60 mg/m2 will be administered on Day 1 of each 21-day cycle. Carboplatin Area Under the Curve (AUC) 5 will be administered on Day 1 of each 21-day cycle.&#xD;
Docetaxel and carboplatin should be administered per institutional guidelines. Treatment will be repeated until disease progression or unacceptable toxicity.&#xD;
Carboplatin: Chemotherapy&#xD;
Docetaxel: Chemotherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with metastatic resistant prostate cancer</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Achieving &gt;= 50% Reduction in PSA According to Prostate Cancer Working Group 3 (PCWG3) Criteria</title>
        <description>Achievement of a PSA50 decline is whether the treatment results in a 50% or greater decline in PSA from baseline PSA prior to therapy</description>
        <time_frame>From Day 1 of treatment and up to 30 days after completion of treatment (typically up to 10 cycles of chemotherapy)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Docetaxel, Carboplatin)</title>
            <description>Docetaxel 60 mg/m2 will be administered on Day 1 of each 21-day cycle. Carboplatin Area Under the Curve (AUC) 5 will be administered on Day 1 of each 21-day cycle.&#xD;
Docetaxel and carboplatin should be administered per institutional guidelines. Treatment will be repeated until disease progression or unacceptable toxicity.&#xD;
Carboplatin: Chemotherapy&#xD;
Docetaxel: Chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving &gt;= 50% Reduction in PSA According to Prostate Cancer Working Group 3 (PCWG3) Criteria</title>
          <description>Achievement of a PSA50 decline is whether the treatment results in a 50% or greater decline in PSA from baseline PSA prior to therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 1 of treatment and up to 30 days after completion of treatment (typically up to 10 cycles of chemotherapy (30 weeks))</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Docetaxel, Carboplatin)</title>
          <description>Docetaxel 60 mg/m2 will be administered on Day 1 of each 21-day cycle. Carboplatin Area Under the Curve (AUC) 5 will be administered on Day 1 of each 21-day cycle.&#xD;
Docetaxel and carboplatin should be administered per institutional guidelines. Treatment will be repeated until disease progression or unacceptable toxicity.&#xD;
Carboplatin: Chemotherapy&#xD;
Docetaxel: Chemotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bruce Montgomery, PI</name_or_title>
      <organization>VA Puget Sound HCS</organization>
      <phone>2062776878</phone>
      <email>rbmontgo@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

